Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Up 8.1% in December

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 530,200 shares, a growth of 8.1% from the November 30th total of 490,400 shares. Based on an average trading volume of 28,200 shares, the days-to-cover ratio is presently 18.8 days. Currently, 9.0% of the shares of the company are short sold.

Institutional Trading of Greenwich LifeSciences

Several hedge funds have recently bought and sold shares of GLSI. Geode Capital Management LLC raised its stake in shares of Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after buying an additional 5,861 shares during the period. State Street Corp increased its holdings in Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after acquiring an additional 3,005 shares in the last quarter. Garden State Investment Advisory Services LLC bought a new stake in Greenwich LifeSciences during the 3rd quarter worth approximately $253,000. Bank of New York Mellon Corp bought a new stake in Greenwich LifeSciences during the 2nd quarter worth approximately $264,000. Finally, Barclays PLC lifted its holdings in Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after purchasing an additional 6,538 shares in the last quarter. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Stock Performance

Shares of GLSI stock traded up $0.32 during mid-day trading on Wednesday, reaching $11.23. 42,190 shares of the company’s stock traded hands, compared to its average volume of 39,041. The firm has a market capitalization of $147.62 million, a PE ratio of -14.04 and a beta of 1.61. Greenwich LifeSciences has a 12 month low of $8.00 and a 12 month high of $21.44. The firm has a 50 day moving average price of $13.29 and a two-hundred day moving average price of $14.27.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.